Immunovant, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immunovant's lead candidate IMVT-1402 600 mg achieved the primary endpoint of ACR20 response in Period 2 of its potentially registrational difficult-to-treat rheumatoid arthritis (D2T RA) trial: 92.5% vs. 75.6% placebo (p=0.0139), with 117 participants randomized (40 on 600mg, 36 on 300mg, 41 placebo). The company halted further development in Sjögren's disease beyond the ongoing Phase 2 trial. FDA discussions are planned for late 2026 on the RA registrational path. Cash position: $722.3M as of September 30, 2026; 206,785,540 shares outstanding.
Why this rating
Positive phase 2b data supports potential commercial pathway; cash runway sufficient for GD launch; modest endpoint (ACR20, not powered secondary endpoints); no major M&A or revenue catalyst yet imminent.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $35.85 ▲ 8.06% | at our read · unknown $33.17 | +10 min · unknown $34.86 ▲ 5.08% | +30 min · unknown $35.31 ▲ 6.45% | +1 hr · unknown $34.98 ▲ 5.44% | +4 hrs · unknown $33.94 ▲ 2.31% |
The stock had already moved -7.46% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.